In this very special podcast, we take a look at the Life Sciences sector in Norway and how this is one of the country's fastest growing sectors, with innovation, funding and IP being central to this growth.
To help us explore this sector in detail, we speak to two people heavily involved in the Norwegian Life Sciences scene: Bjørn Klem, General Manager of the Oslo Cancer Cluster Incubator (OCCI); and Bjørn Steen Skålhegg, CEO of Arctic Pharma, a start-up company developing innovative anti-cancer drugs, and also an OCC member.
Bjørn Klem explains how the OCCI supports its members to accelerate the new development of new cancer diagnostics and medicines, and how IP fits in to that process; Bjørn Steen Skålhegg then explains how Arctic Pharma has grown and developed after being spun-out from another company, how IP has played such an important part in its development, and what they've learnt on their journey so far.
Please click on the image below to listen to this podcast.
The information in this podcast is given as guidance. Legal advice should be sought for particular matters. Dehns accepts no responsibility for any action taken / not taken on the basis of this podcast.
"IP is vital to all drug discovery companies...Investors wouldn't touch us without IP...Secure IP early on, but not too early."